Build status - In Progress

The REFLECT Trial: A Randomized Evaluation oF the TriGuard HDH Cerebral Embolic Protection Device and the TriGUARD 3 Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation

Recruiting
99 years or below
All
Phase 2
40 participants needed
1 Location

Brief description of study

This is a research study designed to look at the safety and effectiveness of the TriGUARD 3 cerebral embolic protection device in patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of the study is to assess whether the TriGUARD 3 can prevent death, stroke, more subtle signs of brain injury, and/or silent brain injury as measured by a magnetic resonance imaging (MRI) study of the brain.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cerebral Embolic Lesion
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 830258

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center